山楂消脂胶囊对非急性期冠心病痰瘀证患者超敏C反应蛋白及基质金属蛋白酶的影响

目的 观察山楂消脂胶囊对非急性期冠心病痰瘀证患者的血清超敏C反应蛋白(Hs-CRP)、基质金属蛋白酶2 (MMP-2)、基质金属蛋白酶9(MMP-9)的影响,以探讨其稳定动脉粥样硬化斑块的作用.方法 将符合诊断标准的110例非急性期冠心病痰瘀证患者随机分为2组.对照组(54例)予基础治疗+血脂康,治疗组(56例)予基础治疗+山楂消脂胶囊,2组均不用他汀类调脂药,疗程6个月.观察2组患者急性心血管事件(MACE)发生率,同时测定治疗前后Hs-CRP、MMP-2、MMP-9、痰浊证计分、血瘀证计分以及MACE发生后各指标的变化.结果 山楂消脂胶囊组的血瘀证、痰浊证计分较治疗前明显降低,优于对照组(P＜0.01),MACE发生率与对照组比较,无统计学意义(P＞0.05).山楂消脂胶囊组可明显降低Hs-CRP、MMP-2、MMP-9,与治疗前比较差异有统计学意义(P＜0.01).结论 山楂消脂胶囊可通过改善冠心病患者的痰浊血瘀状态,抗炎症反应,降低细胞外基质中的MMP-2、MMP-9水平的表达,稳定冠状动脉粥样硬化斑块,减少非急性期冠心病痰瘀证患者MACE的发生.

Effect of Shanzha Xiaozhi Capslue on High-sensitivity C-reactive Protein and Matrix Metalloproteinases in Patients with Non-acute Phase Coronary Heart Disease of Phlegm and Blood Stasis Syndrome

Objective To investigate the effect of Shanzha Xiaozhi Capslue on Hs-CRP, MMP-2 and MMP-9 in patients with non-acute phase coronary heart disease of phlegm and blood stasis syndrome. Methods One hundred and ten patients with non-acute phase coronary heart disease of phlegm and blood stasis syndrome were randomly divided into 2 groups, with 56 cases in the treatment group and 54 cases in the control group. The control group was treated with baseline therapy and Xuezhikang, while the treatment group was treated with baseline therapy and Shanzha Xiaozhi Capslue. They were all treated for 6 months but without statin antilipemic agents. The occurrence of major adverse cardiovascular events （MACE） and the changes of Hs-CRP, MMP-2, MMP-9, scores of blood stasis syndrome and phlegm syndrome in both groups were measured before and after the treatment. Results The scores of blood stasis syndrome and phlegm syndrome in the treatment group were decreased significantly compared with the control group （P〈0.01）. There was no significant difference in MACE occurrence between the two groups （P〉0.05）. After treated with Shanzha Xiaozhi Capslue, the blood levels of Hs-CRP, MMP-2 and MMP-9 were decreased significantly compared with before the treatment （P〈0.01）. Conclusion Shanzha Xiaozhi Capslue can improve the state of phlegm and blood stasis, relieve inflammatory reaction, lower the expression of extracellular MMP-2 and MMP-9, stabilize atherosclerotic plaque of coronary artery, and then reduce the occurrence of MACE with non-acute phase coronary heart disease of phlegm and blood stasis syndrome.